Search research articles
Contact Us
Filters
Showing results (91-100 of 99) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 99 results.
Anticancer Research
|
October 3, 2018
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Anticancer Research
|
September 15, 2019
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model
Hiromichi Oshiro, Yasunori Tome, Tasuku Kiyuna, et al.
Journal of Cellular Biochemistry
|
November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase
Kentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Oncotarget
|
April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Takashi Murakami, Shukuan Li, Qinghong Han, et al.
Chemotherapy
|
January 24, 2019
Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model
Kentaro Miyake, Tasuku Kiyuna, Shukuan Li, et al.
Oncotarget
|
May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model
Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)
|
January 30, 2018
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic
Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cancer Letters
|
January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma
Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Biochemical and Biophysical Research Communications
|
September 1, 2018
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma
Kei Kawaguchi, Takashi Higuchi, Shukuan Li, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 99) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 99 results.
Anticancer Research
|
October 3, 2018
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Anticancer Research
|
September 15, 2019
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model
Hiromichi Oshiro, Yasunori Tome, Tasuku Kiyuna, et al.
Journal of Cellular Biochemistry
|
November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase
Kentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Oncotarget
|
April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Takashi Murakami, Shukuan Li, Qinghong Han, et al.
Chemotherapy
|
January 24, 2019
Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model
Kentaro Miyake, Tasuku Kiyuna, Shukuan Li, et al.
Oncotarget
|
May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model
Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)
|
January 30, 2018
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic
Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cancer Letters
|
January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma
Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Biochemical and Biophysical Research Communications
|
September 1, 2018
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma
Kei Kawaguchi, Takashi Higuchi, Shukuan Li, et al.
Page
of 10